Genmab and Seagen Report P-III Trial (innovaTV 301) Results of Tivdak (tisotumab vedotin-tftv) for Recurrent or Metastatic Cervical Cancer
Shots:
- The P-III trial evaluating Tivdak vs CT alone (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed) in 502 patients. The study was conducted by Seagen in collaboration with Genmab, ENGOT & GOG Foundation
- The trial met its 1EPs of OS at predetermined, independent interim analysis & the 2EPs of investigator-assessed PFS & ORR also demonstrated statistical significance while the safety profile was consistent with the known safety profile of Tivdak & no new safety signals were reported. The results will be submitted at an upcoming medical congress & discussed with regulatory authorities
- Tivdak received accelerated approval from the US FDA for adult patients with recurrent or metastatic cervical cancer with disease progression on or after CT
Ref: Businesswire | Image: Seagen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
